Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity

Circulation

Volumn 106, Issue 19, 2002, Pages 2428-2433

  Sander, Dirk ^a   Winbeck, Kerstin ^a   Klingelhöfer, Jürgen ^a   Etgen, Thorleif ^a   Conrad, Bastian ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Atherosclerosis; Cerebrovascular disorders; Infection; Inflammation; Risk factors

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CIPROFLOXACIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MACROLIDE; PLACEBO; ROXITHROMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTERY DIAMETER; ARTICLE; ATHEROSCLEROSIS; BACTERIAL INFECTION; CARDIOVASCULAR RISK; CAROTID ARTERY THROMBOSIS; CEREBROVASCULAR ACCIDENT; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; COMMON CAROTID ARTERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; C-REACTIVE PROTEIN; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK; ROXITHROMYCIN; SEROLOGIC TESTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUNICA INTIMA; TUNICA MEDIA; ULTRASONOGRAPHY, DOPPLER, DUPLEX;

EID: 0037027478     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000036748.26775.8D     Document Type: Article

References (33)

1. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation. 2002;105:15-21.
2. Ridker PM. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. Circulation. 2002;105:2-4.
3. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: Emerging mechanistic paradigms. Circulation. 1999;100:e20-e28.
4. Zhu J, Quyyumi AA, Norman JE, et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol. 2000:85:140-146.
5. Espinola-Klein C, Rupprecht HJ. Blankenberg S. et al. Are morphological or functional changes in the carotid artery wall associated with Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, or herpes simplex virus infection? Stroke. 2000;31:2127-2133.
6. Burnett MS, Gaydos CA, Madico GE, et al. Atherosclerosis in apoE knockout mice infected with multiple pathogens. J Infect Dis. 2001;183: 226-231.
7. Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404-407.
8. Anderson JL, Muhlestein JB, Carlquist J. et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation. 1999;99: 1540-1547.
9. Gurfinkel EP, Bozovich G. Emerging role of antibiotics in atherosclerosis. Am Heart J. 1999;138:S537-S538.
10. Sinisalo J, Mattila K, Valtonen V, et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation. 2002;105:1555-1560.
11. Parchure N, Zouridakis EG, Kaski JC. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation. 2002;105: 1298-1303.
12. Wiesli P, Czerwenka W, Meniconi A, et al. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: A randomized, double-blind, placebo-controlled trial. Circulation. 2002;105:2646-2652.
13. Zhu J, Nieto FJ, Horne BD, et al. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation. 2001;103:45-51.
14. Danesh J, Whincup P, Walker M, et al. Chlamydia pneumoniae IgG titers and coronary heart disease: prospective study and meta-analysis. Br Med J. 2000;321:208-213.
15. Gieffers J, Fullgraf H, Jahn J. et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation. 2001;103:351-356.
16. Rothstein NM, Quinn TC, Madico G, et al. Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae. J Infect Dis. 2001;183:232-238.
17. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340:14-22.
18. Sander D, Kukla C, Klingelhofer J, et al. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: A 3-year follow-up study. Circulation. 2000;102:1536-1541.
19. Sander D, Winbeck K, Klingelhofer J. et al. Enhanced progression of early carotid atherosclerosis is related to Chlamydia pneumoniae (Taiwan acute respiratory) seropositivity. Circulation. 2001;103:1390-1395.
20. Wang S. The microimmunofluorescence test for Chlamydia pneumoniae infection: Technique and interpretation. J Infect Dis. 2000;181(suppl 3):S421-S425.
21. Markus HS, Sitzer M, Carrington D, et al. Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerosis. Circulation. 1999;100:832-827.
22. Melissano G, Blasi F, Esposito G, et al. Chlamydia pneumoniae eradication from carotid plaques: Results of an open, randomised treatment study. Eur J Vasc Endovasc Surg, 1999;18:355-359.
23. Neumann F, Kastrati A, Miethke T. et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): A randomised, double-blind, placebo-controlled trial. Lancet. 2001;357:2085-2089.
24. Muhlestein JB. Chlamydia pneumoniae-induced atherosclerosis in a rabbit model. J Infect Dis. 2000;181(suppl 3):S505-S507.
25. Fong IW. Antibiotics effects in a rabbit model of Chlamydia pneumoniae-induced atherosclerosis. J Infect Dis. 2000:181(suppl 3):S514-S518.
26. Roivainen M, Viik-Kajander M, Palosuo T. et al. Infections, inflammation, and the risk of coronary heart disease. Circulation, 2000;101: 252-257.
27. Ross R. Atherosclerosis: An inflammatory disease, N Engl J Med. 1999; 340:115-126.
28. Dechend R, Maass M, Gieffers J, et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-κB and induces tissue factor and PAI-1 expression: A potential link to accelerated arteriosclerosis. Circulation. 1999;100:1369-1373.
29. Rodel J, Woytas M, Groh A, et al. Production of basic fibroblast growth factor and interleukin 6 by human smooth muscle cells following infection with Chlamydia pneumoniae. Infect Immun. 2000;68: 3635-3641.
30. Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum. 1992;35: 982-984.
31. Johnston SC, Messina LM, Browner WS, et al. C-reactive protein levels and viable Chlamydia pneumoniae in carotid artery atherosclerosis. Stroke. 2001;32:2748-2752.
32. Gurfinkel E, Bozovich G, Beck E, et al. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: The final report of the ROXIS study. Eur Heart J. 1999;20:121-127.
33. Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: Primary clinical results of the ACADEMIC study. Circulation. 2000;102:1755-1760.